Embryonic stem cells (ESCs) are pluripotent cells capable of developing into any cell type in the embryo, originating from the inner cell mass (ICM) of the blastocyst or epiblast cells. This pluripotent nature of human embryonic stem cells (hESCs) enables them to differentiate into any cell type derived from the three germ layers, making them vital for understanding cell development.

ESCs serve as a universal source of cells in regenerative medicines and various other studies, in which they have shown their ability to produce functional cells of various types that have been used successfully in various animal diseases. In addition, ESCs exhibit hypertranscription and open chromatin conformation, enabling rapid transcriptional changes during differentiation¹.

History of embryonic stem cells

The concept underlying ESCs traces its origins to Theodor Boveri and Valentin Häcker, who first used the term “stem cell” to describe cells responsible for giving rise to the germline.

Later, Alexander Maximow introduced the idea of a precursor cell capable of differentiating into all blood cell types, a notion expanded by Ernst Haeckel with his development of the “Stammzellen” concept. In the 1960s, Ernest McCulloch and James Till provided key evidence of stem cell self-renewal and colony-forming capabilities, along with Georges Mathé advancing the field by pioneering allogeneic bone marrow transplantation².

Key milestones in embryonic stem cell research include²:

• In 1981, Sir Martin Evans and Matthew Kaufman cultivated mouse ESCs in the laboratory for the first time.
• In 1998, James Thomson discovered hESCs and published his findings in “Embryonic stem cell lines derived from human blastocysts.”
• In 2007, James Thomson developed human-induced pluripotent stem cells (hiPSC) by converting skin cells into cells resembling ESCs.
• In 2012, Shinya Yamanaka and John Gurdon were awarded the Nobel Prize for their discovery that mature cells can be reprogrammed into pluripotent stem cells².

Biological characteristics of embryonic stem cells

ESCs possess the ability to differentiate into any cell type within the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotent nature allows them to develop into diverse tissues, such as neurons, muscle cells, and epithelial cells, making them a cornerstone for studying cell differentiation and development.

ESCs have the capacity for unlimited self-renewal, maintaining their undifferentiated state through numerous cell divisions. This property ensures a consistent supply of stem cells for long-term research and therapeutic applications.

The ICM of preimplantation blastocysts, morula, or even a single blastomere serves as a source of self-renewing, pluripotent cells that possess the ability to proliferate in vitro. The signaling pathways and transcriptional networks maintaining pluripotency differ between species, with key factors being essential for their stability. They can express pluripotency markers such as NANOG, Rex-1, TRA-1, TRA-1-60, SSFA-4, SSFA-3, Oct-4, and alkaline phosphatases. They also exhibit telomerase activity³.

The gene regulatory network of ESC is controlled by a set of specific transcription factors, such as Nanog, Sox2, Klf4, and Oct4, which work together to maintain embryonic stem cell identity and pluripotency⁴.

How are embryonic stem cells obtained?

ESCs are isolated from the ICM of blastocysts using techniques such as immunosurgery, mechanical isolation, and laser dissection. Some methods involve culturing the ICM in a conditioned medium from teratocarcinoma stem cells, which contain growth factors that support ESC proliferation and prevent differentiation⁵.

Process of isolation from the inner cell mass of a blastocyst

ESCs are extracted from the ICM of a blastocyst (an embryonic stage of 4-5 days old and contains 50-150 cells), which forms after fertilization and early cell divisions. The ICM, located inside the blastocyst, develops into the embryo, while the outer trophoblast forms extra-embryonic tissues such as the placenta⁶.

Methods such as mechanical dissection, laser-assisted biopsy, and immunosurgery can be used.

Mechanical dissection: This method involves removing the homogenous ICM from the trophoblast layer with a needle7. It is fast and cost-effective and eliminates the problem of xeno-components in immunosurgery⁸.

Laser-assisted biopsy: This technique separates specific cell groups from a blastocyst using targeted laser pulses. The blastocyst is held in place with pipettes, and precise laser pulses are applied to create a controlled split. This process allows the isolation of the desired ICM while preserving other cell structures⁹.

Immunosurgery: Immunosurgical techniques are used to isolate ESCs by selectively removing the outer cell layer of a blastocyst. The protective outer layer is first dissolved using an enzyme, exposing the embryo to antibodies that bind only to outer cells without affecting the ICM. After treatment with a complement solution to lyse the labeled outer cells, the intact ICM is isolated and cultured for further use¹⁰.

Although these techniques enable the extraction of pluripotent cells capable of differentiating into any body cell, ethical concerns arise owing to the destruction of embryos during the process. To address these issues, alternative methods such as isolating ESCs from a single blastomere during preimplantation genetic testing have been developed, offering a less destructive approach.

After isolation, the ICM is cultured on feeder layers or synthetic matrices to generate ESC lines. Further, multiplex kits such as the embryonic stem cell marker panel (Human: Oct4, Nanog, Tra-1-60 (R), SOX2, SSEA4) can be used to characterize ESCs and know their differentiation patterns.

Sources of human embryonic stem cells

Human embryos for ESC isolation are primarily sourced from assisted reproductive technology (ART) programs. Key sources include^11,12:

• Good-quality spare embryos left after in vitro fertilization (IVF).
• Embryos collected from an abortion or a terminated pregnancy.
• Cryopreserved spare embryos that are no longer needed by couples.
• Poor-quality embryos are discarded due to low viability, which can be improved in vitro.

Recent research shows that ESCs can be derived by nuclear transfer from wild-derived mouse strains using peripheral blood leukocytes as nuclear donors. This demonstrates a novel method for preserving the genetic resources of these strains with confirmed pluripotency, normal karyotype, and germline transmission capability¹³.

Culture techniques for maintaining stem cell lines

The isolated cells from the embryo can be cultured by using:

• Feeder-based culture system: ESCs are cultured on mouse embryonic fibroblasts (MEFs) to provide necessary growth factors and extracellular matrix support. This layer offers signals for its growth and development. For instance, MEFs secrete factors such as fibroblast growth factor-2 (FGF2), extracellular matrix proteins, activin, and gremlin 1 (a bone morphogenetic factor inhibitor), which are crucial for sustaining ESC pluripotency¹⁴.
• Non-feeder-based culture system: ESCs are grown on synthetic matrices that remove the limitations of contamination and viability of the feeder layer. For example, engineered growth substrates made from biological or synthetic materials, combined with chemically defined media, can effectively replace the feeder cells, supporting hPSC pluripotency and self-renewal in a standardized, sustainable manner for clinical applications¹⁵.

Methods to maintain human embryonic stem cells

Efficient cryopreservation of hESCs is essential for preserving early-passage stocks; however, it is also challenging owing to high cell death and differentiation after freezing and thawing¹⁶.

Common methods for cryopreservation include¹⁷:

• Slow freezing with dimethylsulfoxide (DMSO) uses programmable freezers to control the freezing rate. It balances ice crystal formation and cell dehydration to minimize cellular damage. This approach helps prevent ice crystals from forming inside the cells during freezing. It typically results in poor outcomes but can be improved with adjustments to protocols and additional cryoprotectants.
• Vitrification is a rapid cryopreservation technique where a supercooled liquid transforms into a glass-like solid without forming ice crystals. This process uses cryoprotectants at concentrations of 40% (v/v) or higher to prevent cellular damage. It ensures better preservation by avoiding ice crystal formation during freezing. It yields high survival rates but is labor-intensive
• Approaches such as adding extracellular matrix components or Rho-associated kinase inhibitors and freezing hESC colonies on specific substrates have enhanced post-thaw recovery and maintained stem cell characteristics¹⁷.

Stable karyotype and genetic integrity of embryonic stem cells

ESCs show a stable euploid karyotype over extended culture periods, reflecting the preservation of their genomic integrity. This stability is sustained through the coordinated activity of specific signaling pathways as well as regulatory proteins and peptides that govern both self-renewal and genomic maintenance^18,19.

Depletion of key genes involved in DNA replication, checkpoint regulation, and genome stability can cause DNA damage, activate tumor protein 53 (p53), and lead to ESC differentiation, highlighting the essential role of genomic integrity in ESC microenvironment¹⁹.

In vitro differentiation into specialized cell types

In vitro differentiation of ESCs involves creating specific environmental conditions, such as altering the growth factors and signaling molecules present, in order to direct ESCs into specialized cell types³. This process is carefully controlled to mimic the developmental cues found in the embryo, ensuring the ESCs transition into various lineages, simultaneously retaining their potential for therapeutic applications.

For example, heart diseases often result in the loss of functional cardiomyocytes, leading to impaired cardiac function. A study involved transplanting approximately 750 million cryopreserved human ESC-derived cardiomyocytes into macaque monkeys with significant myocardial infarctions. The results showed enhanced cardiac function and remuscularization of the damaged heart tissue²⁰.

Epigenetic plasticity and gene regulation

ESCs exhibit remarkable epigenetic plasticity, which plays a vital role in regulating their pluripotency and differentiation potential.

Chromatin modifications, such as post-translational histone changes, DNA methylation, and the involvement of proteins such as heterochromatin protein 1 (HP1), are essential for controlling ESC function and guiding their differentiation. This offers potential therapeutic applications for diseases such as Parkinson’s and diabetes²¹.

In ESCs, DNA methylation patterns are dynamically regulated to maintain pluripotency and enable differentiation. For example, the promoters of pluripotency-associated genes such as Oct4 and Nanog are typically hypomethylated, allowing active transcription. During differentiation, these promoters become hypermethylated, leading to gene silencing and commitment to specific lineages. This dynamic regulation of DNA methylation is crucial for the proper control of gene expression during development²².

Histone modifications can also influence gene expression in ESCs. For example, the genes with H3K4me3 modification are actively transcribed, contributing to the maintenance of pluripotency and self-renewal in ESCs. The presence of H3K4me3 at specific promoters ensures that essential genes remain accessible for transcription, thereby playing a crucial role in cell identity and function. However, H3K27me3 in ESCs marks genes involved in differentiation pathways, keeping them repressed to maintain the stem cell state²³.

Applications of embryonic stem cells in research

Recent advancements in stem cell research have enabled the creation of in vitro models that mimic early mammalian development, offering valuable insights into embryogenesis. These models, derived from human and mouse stem cells, provide powerful tools for understanding developmental processes and modeling diseases, with potential applications in clinical practice.

Regenerative medicine and modeling diseases

ESCs show promising potential in spinal-cord injury treatment, where their transplantation and trans-differentiation into specific cell types showed improved mobility and sensory functions²⁴.

ESCs also show significant potential in treating a wide range of diseases through their ability to differentiate into various cell types. For example, ESC-derived cone cells have been used to restore vision in age-related macular degeneration (AMD), just like ESC-derived cardiomyocytes help regenerate heart tissue in cardiovascular diseases²⁵.

Additionally, ESCs show promise in applications such as liver regeneration, diabetes treatment through insulin-producing cells, cartilage repair in osteoarthritis, and the development of biological pacemakers. These advancements highlight ESCs as a versatile tool in regenerative medicine²⁵.

Creation of in vitro models for studying early human development

Embryonic stem cell-based models of early human embryonic development offer new insights into developmental biology and human reproduction, focusing on the first two weeks of embryo development, cell lineage, and stem cell derivation²⁶.

ESCs aid in embryoid body formation by aggregating spontaneously into 3D suspension. This structure mimics the early embryonic development models that help make it a strong pillar in regenerative medicines²⁷.

Recent advancements in stem cell research provide future directions in creating in vitro models to simulate intercellular communication in early embryo development. For example, organoids can be used in modeling complex processes such as gastrulation. Studies have demonstrated that aggregates of mouse ESCs can self-organize into structures exhibiting symmetry breaking, germ layer specification, and axial organization, closely mirroring early embryonic development stages.

Blastoids, a stem cell-derived structure, can be used in the formation of the three lineages: trophectoderm, epiblast, and primitive endoderm. These blastoids not only mimic the morphology and gene expression patterns of natural blastocysts but also exhibit the capacity to attach to hormonally stimulated endometrial cells, modeling the early stages of implantation^28,29.

Scientific techniques and technologies in embryonic stem cell research

Scientific techniques in embryonic stem cell research include methods such as gene editing, cell reprogramming, and tissue culture to study development and potential medical applications. Advanced technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) gene editing, organoid models, and 3D bioprinting are also being explored to enhance the understanding and therapeutic use of stem cells^30,31.

Directed differentiation techniques for obtaining specific cell types

Directed differentiation of ESCs can be achieved by expressing specific transcription factors, which guide the cells to form desired lineages such as neural, muscle, liver, and pancreatic cells. For example, the overexpression of transcription factors, such as NEUROG2, has been shown to efficiently induce neuronal differentiation in ESCs, leading to the formation of functional neurons. Forced expression of MYOD1in ESCs promotes differentiation into myogenic lineage, resulting in the formation of muscle cells. The induction of PDX1, along with other pancreatic transcription factors, helps in differentiating ESCs into pancreatic progenitors capable of further maturation into insulin-producing cells³².

Advances in developmental biology have identified key pathways for ESC differentiation, leading to protocols for generating a range of cell types such as hematopoietic cells and neurons. For example, by mimicking the embryonic hematopoietic niche and modulating pathways such as Notch and Wnt, ESCs have been successfully directed to differentiate into hematopoietic progenitor cells³².

Additionally, genetic modifications, including the expression or silencing of developmental genes, along with fluorescent reporter genes, enable precise control and high-throughput screening of the differentiation processes of ESC³³.

Genetic editing advances in ESC research

The use of advanced gene-editing tools such as CRISPR-Cas9, zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs) has markedly improved the precision and efficiency of modifying ESC genomes^34,35.

These tools enable the creation of in vitro human disease models, offering a more accurate and controllable alternative to conventional animal models. Laser direct-write (LDW) bioprinting technology has been utilized to form and control embryoid bodies (EBs) from mouse ESCs, aiding directed cardiogenesis³¹. For example, a study showed that LDW can be used to print mouse ESCs onto substrates, controlling both the size of the initial cell colonies and the local cell density. The researchers found that higher printing densities led to the formation of larger EBs, suggesting that precise manipulation of cell placement directly influences EB morphology³⁶.

By combining somatic cell reprogramming (iPSCs) with gene editing, researchers can effectively study human diseases at the molecular level³⁷.

Ethical and regulatory aspects of embryonic stem cell research

ESC research involves complex ethical considerations, especially regarding the use of human embryos, which some believe should not be used for scientific purposes. Regulations surrounding ESC research aim to ensure ethical practices, including obtaining informed consent from donors and ensuring minimal harm to embryos².

Despite the promise ESCs hold for medical breakthroughs, the discussion continues on how to balance these advancements with moral and legal concerns related to the use of embryos.

• Stem cell research raises ethical concerns about the use of embryos, donor privacy, and the accessibility of medical and therapeutic technologies. Key issues include²:
• Obtaining informed consent for donor materials.
• The safety and efficacy of treatments.
• Addressing the risks involved in procedures such as bone marrow cell isolation.

Balancing the moral implications with the potential to develop innovative therapies for severe diseases remains a vital challenge.

Current guidelines and regulations

Current guidelines for embryonic stem cell research stress informed consent from donors, careful consideration of intellectual property, and ethical concerns about using surplus embryos from IVF.

The International Society for Stem Cell Research (ISSCR) permits the use of embryos within the first 14 days, citing that they do not constitute a “human person,” while also allowing the use of cadaveric embryonic tissue from spontaneous or voluntary abortions with the donor’s informed consent.

However, creating human embryos solely for research is prohibited, and transparency about the source of research funding and the donor’s rights remains essential².

To address bioethical concerns about stem cell extraction, attempts have been made to extract stem cells from a 6-8 cell embryo three days after fertilization without affecting its development. The embryo is then implanted in the uterus after the biopsy².

Induced pluripotent stem cells (iPSCs) offer an alternative to the use of ESCs. iPSCs are generated by reprogramming somatic cells into a pluripotent state, and since they are derived from the individual’s own cells, they do not raise the ethical concerns associated with ESCs³⁷.

Comparison with adult stem cell research

Adult stem cells (ASCs) do not present legal or bioethical concerns, as they do not endanger the donor and require only informed consent. Unlike ESCs, ASCs can be ethically sourced without involving cloning, with strict guidelines on the anonymity of donors and financial transactions to ensure ethical practices².

Challenges and future directions in embryonic stem cell research

Challenges in embryonic stem cell research include immune rejection in therapeutic applications and ensuring the stability of pluripotency during differentiation. Future directions focus on advancing gene-editing techniques, developing personalized therapies, and improving methods to overcome ethical and immunological barriers³⁸.

Technical challenges in cell culture and maintaining cell lines

Maintaining human ESCs requires precise culture conditions, including feeder-free and serum-free environments, to ensure their pluripotency and self-renewal capabilities.

Rigorous quality control measures, such as karyotyping and immunogenicity assays, are vital for ensuring the therapeutic viability of hESCs³⁹.

Traditional 2D culturing techniques limit large-scale expansion, prompting the adoption of 3D culturing methods such as spheroids and bioreactors to better replicate in vivo conditions⁴⁰.

Innovations and trends in stem cell therapy

Innovations in stem cell therapy, including induced pluripotent stem cells (iPSCs) and genetic engineering, are expanding therapeutic applications, particularly in regenerative medicine and treating genetic disorders.

Future trends focus on ensuring safety and efficacy, developing xeno-free culture methods, and integrating stem cells into drug discovery and personalized medicine for advanced clinical applications⁴¹.

FAQs

What are human embryonic stem cells used for in research?

Human embryonic stem cells (hESCs) are used in research to study early human development and cell differentiation. They can develop into any cell type, making them valuable for investigating potential treatments for diseases such as Parkinson’s and diabetes. Researchers also use hESCs to explore drug development and testing and the effects of genetic mutations on development.

Why are embryonic stem cells important for medical research?

Embryonic stem cells are important for medical research because they have the unique ability to develop into any type of cell in the body. This makes them vital for studying tissue regeneration and repair. They are also used to explore potential treatments for various diseases, including genetic disorders, degenerative conditions, and injuries.

Can embryonic stem cells be used to grow organs?

Yes, embryonic stem cells have the potential to be used in growing organs due to their ability to differentiate into various cell types. Researchers are exploring ways to use these cells for organ regeneration, which could address organ shortages for transplants. While still in the early stages, this research holds promise for creating functional organs in the future.

Are there alternatives to using embryonic stem cells?

Yes, there are alternatives to using embryonic stem cells, such as induced pluripotent stem cells (iPSCs), which are reprogrammed adult cells that behave like embryonic stem cells. Adult stem cells, found in various tissues, can also be used for research and regenerative medicine. Additionally, research into organoids and other techniques is advancing as potential alternatives to stem cell therapies.

What are the four major types of stem cells?

Stem cells are classified based on their ability to differentiate into various cell types:

·         Totipotent: These stem cells can differentiate into all cell types, including the extra-embryonic tissues such as the placenta. The zygote and the first few divisions of an embryo are considered totipotent.

·         Pluripotent: Pluripotent stem cells can differentiate into almost all cell types except for extra-embryonic tissues. Embryonic stem cells and induced pluripotent stem cells (iPSCs) are examples of pluripotent cells.

·         Multipotent: Multipotent stem cells can give rise to a limited range of cell types within a specific tissue or organ. Adult stem cells, such as hematopoietic stem cells (which form blood cells), are examples of multipotent cells.

·         Unipotent: These stem cells can produce only one cell type, but they still can self-renew. They are typically found in adult tissues, where they maintain and repair their specific tissue type.

How many cell types can embryonic stem cells differentiate into?

Embryonic stem cells can differentiate into more than 200 different cell types in the human body. They are pluripotent, meaning they have the potential to form any cell type except those required for extra-embryonic tissues such as the placenta. This capability makes them highly valuable for regenerative medicine and research.

Meta title: Embryonic stem cells | Abcam

Meta description: Discover how embryonic stem cells (ESCs) are revolutionizing regenerative medicine. Explore their role in tissue repair and advancements in treating diseases.

Slug: /embryonic-stem-cells

References:

1. 1.      Gupta, S., Santoro, R. Regulation and Roles of the Nucleolus in Embryonic Stem Cells: From Ribosome Biogenesis to Genome Organization. Stem Cell Reports. 15 (6), 1206–1219 (2020).

   2.      Charitos, I.A., Ballini, A., Cantore, S., et al. Stem Cells: a Historical Review about Biological, Religious, and Ethical Issues. Stem Cells International. 2021, 1–11 (2021).

   3.      Kiecker, C., Bates, T., Bell, E. Molecular specification of germ layers in vertebrate embryos. Cellular and Molecular Life Sciences. 73 (5), 923–947 (2015).

   4.      Smith, A. Propagating pluripotency – The conundrum of self‐renewal. BioEssays. 46 (12) (2024).

   5.      Vazin, T., Freed, W.J. Human embryonic stem cells: Derivation, culture, and differentiation: A review. Restorative Neurology and Neuroscience. 28 (4), 589–603 (2010).

   6.      Khan, Y.S., Ackerman, K.M. Embryology, week 1. StatPearls. (2023).

   7.      Li, B., Xu, L., Lu, W.Y., et al. A whole-mechanical method to establish human embryonic stem cell line HN4 from discarded embryos. Cytotechnology. 62 (6), 509–518 (2010).

   8.      Strom, S., Inzunza, J., Grinnemo, K.H., et al. Mechanical isolation of the inner cell mass is effective in derivation of new human embryonic stem cell lines. Human Reproduction. 22 (12), 3051–3058 (2007).

   9.      Tanaka, N., Takeuchi, T., Neri, Q.V., et al. Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: applications and preliminary results in a murine model. Journal of Translational Medicine. 4 (1), 20 (2006).

   10.  Amit, M., Itskovitz-Eldor, J. Isolation, Characterization and Maintenance of Primate Embryonic Stem Cells. Academic Press. 351–363 (2009).

   11.  Mehta, R.H. Sourcing human embryos for embryonic stem cell lines: Problems & perspectives. The Indian Journal of Medical Research. 140 (Suppl 1), S106 (2014).

   12.  Derivation of embryonic stem cells from wild-derived mouse strains by nuclear transfer using peripheral blood cells. Scientific Reports. 13 (1) (2023).

   13.  1Watanabe, N., Hirose, M., Hasegawa, A., et al. Derivation of embryonic stem cells from wild-derived mouse strains by nuclear transfer using peripheral blood cells. Scientific Reports. 13 (1) (2023).

   14.  Llames, S., García-Pérez, E., Meana, Á., et al. Feeder Layer Cell Actions and Applications. Tissue Engineering Part B: Reviews. 21 (4), 345–353 (2015).

   15.  Yang, K., Lee, J., Cho, S.W. Engineering Biomaterials for Feeder-Free Maintenance of Human Pluripotent Stem Cells. International Journal of Stem Cells. 5 (1), 1–5 (2012).

   16.  Lee, J.E., Lee, D.R. Human Embryonic Stem Cells: Derivation, Maintenance and Cryopreservation. International Journal of Stem Cells. 4 (1), 9–17 (2011).

   17.  Chen, H., Zhang, L., Meng, L., et al. Advantages of vitrification preservation in assisted reproduction and potential influences on imprinted genes. Clinical Epigenetics. 14 (1) (2022).

   18.  Zhong, L., Gordillo, M., Wang, X., et al. Dual role of lipids for genome stability and pluripotency facilitates full potency of mouse embryonic stem cells. PubMed. 14 (8), 591–602 (2023).

   19.  Su, J., Zhu, D., Huo, Z., et al. Genomic Integrity Safeguards Self-Renewal in Embryonic Stem Cells. Cell Reports. 28 (6), 1400–1409.e4 (2019).

   20.  Liu, Y.W., Chen, B., Yang, X., et al. Human embryonic stem cell–derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nature Biotechnology. 36 (7), 597–605 (2018).

   21.  Přikrylová, T. Epigenetics and chromatin plasticity in embryonic stem cells. World Journal of Stem Cells. 5 (3), 73 (2013).

   22.  Boland, M.J., Nazor, K.L., Loring, J.F. Epigenetic regulation of pluripotency and differentiation. Circulation Research. 115 (2), 311–324 (2014).

   23.  Kumar, D., Cinghu, S., Oldfield, A.J., et al. Decoding the function of bivalent chromatin in development and cancer. Genome Research. 31 (12), 2170–2184 (2021).

   24.  Kim, Y., Kim, I., Shin, K. A new era of stem cell and developmental biology: from blastoids to synthetic embryos and beyond. Experimental & Molecular Medicine. 55 (10), 2127–2137 (2023).

   25.  Qu, Z., Guan, Y., Cui, L., et al. Transplantation of rat embryonic stem cell-derived retinal progenitor cells preserves the retinal structure and function in rat retinal degeneration. Stem Cell Research & Therapy. 6 (1) (2015).

   26.  Shahbazi, M.N., Pasque, V. Early human development and stem cell-based human embryo models. Cell Stem Cell. 31 (10), 1398–1418 (2024).

   27.  Bratt-Leal, A.M., Carpenedo, R.L., McDevitt, T.C. Engineering the embryoid body microenvironment to direct embryonic stem cell differentiation. Biotechnology Progress. 25 (1), 43–51 (2009).

   28.  Simunovic, M., Brivanlou, A.H. Embryoids, organoids and gastruloids: new approaches to understanding embryogenesis. Development. 144 (6), 976–85 (2017).

   29.  Heidari Khoei, H., Javali, A., Kagawa, H., et al. Generating human blastoids modeling blastocyst-stage embryos and implantation. Nature Protocols. (2023).

   30.  Yang, S., Hu, H., Kung, H., et al. Organoids: The current status and biomedical applications. MedComm. 4(3), e274 (2023).

   31.  Ong, C.S., Yesantharao, P., Huang, C.Y., et al. 3D bioprinting using stem cells. Pediatric Research. 83(1-2), 223–231 (2017).

   32.  Oh, Y., Jang, J. Directed Differentiation of Pluripotent Stem Cells by Transcription Factors. Molecules and Cells. 42(3), 200–209 (2019).

   33.  Giudice, A., Trounson, A. Genetic modification of human embryonic stem cells for derivation of target cells. Cell Stem Cell. 2(5), 422–433 (2008).

   34.  Ruan, Y., Wang, J., Yu, M., et al. A multi-omics integrative analysis based on CRISPR screens re-defines the pluripotency regulatory network in ESCs. Communications Biology. 6(1) (2023).

   35.  Gao, X., Xu, C., Asada, N., et al. The hematopoietic stem cell niche: from embryo to adult. Development (Cambridge, England). 145(2) (2018).

   36.  Dias, A.D., Unser, A.M., Xie, Y., et al. Generating size-controlled embryoid bodies using laser direct-write. Biofabrication. 6(2) (2014).

   37.  Cerneckis, J., Cai, H., Shi, Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduction and Targeted Therapy. 9(1) (2024).

   38.  Fu, X., Xu, Y. Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. Genome Medicine. 4 (6) (2012).

   39.  Dakhore, S., Nayer, B., Hasegawa, K. Human Pluripotent Stem Cell Culture: Current Status, Challenges, and Advancement. Stem Cells International. 2018, 1-17 (2018).

   40.  McKee, C., Chaudhry, G.R. Advances and challenges in stem cell culture. Colloids and Surfaces B: Biointerfaces. 159, 62–77 (2017).

   41.  Yamanaka, S. Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges. Cell Stem Cell. 27(4), 523–531 (2020).